Clinical Trial Update: Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia [Phase 2]

View source ↗

Summary

This is a Phase 2 pediatric safety and pharmacokinetics study of luspatercept (ACE-536) in children with beta-thalassemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Beta-Thalassemia | Phase 2 | Status: RECRUITING